The aberrant upregulation of Cyclin A–CDK2 activity is an important biological feature of tumor cells, and in some cancer cells, extremely active Cyclin A–CDK2 activity is frequently detected, and Cyclin A–CDK2 has emerged as an important target for the treatment of cancer. This evidence concerns the gene CCNA2 and cancer.